An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
A phase 2 trial of Ruxolitinib, Capecitabine, Regorafenib in colorectal cancer, run by Incyte Corporation, active and no longer recruiting.
Overview
An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib is a phase 2 interventional study registered as NCT02955940 by Incyte Corporation, with 10 participants enrolled, started 2016-11-30 and due to reach its primary completion in 2027-09-30. Interventions recorded: Ruxolitinib, Capecitabine, Regorafenib. Conditions listed: Pancreatic Cancer, Colorectal Cancer (CRC), Breast Cancer, Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialRESPONSE
Shares Ruxolitinib, Incyte.
- TrialA Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal Cancer
Shares Capecitabine, Colorectal cancer.
- TrialRollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)
Shares Ruxolitinib, Incyte.
- TrialTATE and Pembrolizumab (MK3475) in mCRC and NSCLC
Shares Regorafenib, Colorectal cancer.
- TreatmentINCA33890
Shares Incyte, Colorectal cancer.
- TrialA Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
Shares Incyte, Colorectal cancer.
- TrialA Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients.
Shares Capecitabine, Colorectal cancer.
- TrialStudy of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
Shares Regorafenib, Colorectal cancer.